Catalyst Pharmaceuticals Inc  

(Public, NASDAQ:CPRX)   Watch this stock  
Find more results for CPRX
4.92
-0.31 (-5.93%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.86 - 5.28
52 week 2.15 - 5.80
Open 5.21
Vol / Avg. 664,740.00/1.41M
Mkt cap 428.91M
P/E     -
Div/yield     -
EPS -0.24
Shares 82.01M
Beta 0.14
Inst. own 48%
Aug 12, 2015
Q2 2015 Catalyst Pharmaceutical Partners Inc Earnings Release (Estimated) Add to calendar
Jun 2, 2015
Catalyst Pharmaceuticals Inc at Jefferies Global Healthcare Conference
May 15, 2015
Catalyst Pharmaceutical Partners Inc Annual Shareholders Meeting (Estimated)
May 12, 2015
Q1 2015 Catalyst Pharmaceutical Partners Inc Earnings Call
May 11, 2015
Q1 2015 Catalyst Pharmaceutical Partners Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -36.18% -44.77%
Return on average equity -42.61% -54.77%
Employees 12 -
CDP Score - -

Address

355 Alhambra Cir Ste 1500
CORAL GABLES, FL 33134-5038
United States - Map
+1-305-5292522 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. Firdapse is used for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). CPP-115 is used for the treatment of addiction and epilepsy. CPP-109 is used to treat addiction. The Company is conducting a Phase III trial to determine the safety and efficacy of Firdapse in the treatment of LEMS. CPP-115 has been granted Orphan Drug Designation by the food and drug administration (FDA) for the treatment of infantile spasms and Orphan Medicinal Product Designation in the European Union, for West syndrome (a form of infantile spasms).

Officers and directors

Patrick J. McEnany Chairman of the Board, President, Chief Executive Officer
Age: 67
Bio & Compensation  - Reuters
Alicia Grande CPA Chief Financial Officer, Vice President, Treasurer
Age: 44
Bio & Compensation  - Reuters
Steven R. Miller Ph.D. Chief Operating Officer, Chief Scientific Officer
Age: 53
Bio & Compensation  - Reuters
David D. Muth Executive Vice President, Chief Commercial Officer
Age: 60
Bio & Compensation  - Reuters
M. Douglas Winship Vice President - Regulatory Operations
Age: 66
Bio & Compensation  - Reuters
David J. Caponera Vice President - Patient Advocacy & Reimbursement
Age: 58
Bio & Compensation  - Reuters
Bernardino Mosquera M.D. Vice President - Clinical Operations
Age: 47
Bio & Compensation  - Reuters
Charles B. O'Keeffe Lead Independent Director
Age: 75
Bio & Compensation  - Reuters
Gary Ingenito M.D. Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters
Richard J. Daly Director
Age: 53
Bio & Compensation  - Reuters